72 related articles for article (PubMed ID: 7645953)
1. DNA-protein cell content of lymphokine activated killer (LAK) and target cells in coculture.
Nano R; Barni S; Capelli E; Prosperi E; Lavezzi L; Salvucci O
Anticancer Res; 1995; 15(3):751-4. PubMed ID: 7645953
[TBL] [Abstract][Full Text] [Related]
2. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
[TBL] [Abstract][Full Text] [Related]
4. Phenotypical study of human lymphokine-activated killer (LAK) cells.
Barral AM; García CA
Neoplasma; 1989; 36(5):583-8. PubMed ID: 2682296
[TBL] [Abstract][Full Text] [Related]
5. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
Donskov F; Basse PH; Hokland M
Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
Reiter Z; Taylor MW
Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
[TBL] [Abstract][Full Text] [Related]
7. Morphofunctional characterization of lymphokine activated killer (LAK) cells in vitro.
Nano R; Capelli E; Gerzeli G
Boll Soc Ital Biol Sper; 1995; 71(7-8):181-7. PubMed ID: 8519494
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
9. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
10. Cancer cell cycle and adoptive immunotherapy using lymphokine-activated killer cells.
Ejiri Y; Ohara M; Suzuki T; Kasukawa R
Fukushima J Med Sci; 1997 Dec; 43(2):61-73. PubMed ID: 9640842
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
13. Tumor target binding induces phosphorylation of two M(r) 65,000 lymphokine-activated killer proteins.
Frederick MJ; Rodriguez LV; Johnston DA; Grimm EA
Cancer Res; 1996 Jan; 56(1):127-37. PubMed ID: 8548752
[TBL] [Abstract][Full Text] [Related]
14. [Apoptosis of tumor cells in lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity].
Dong H; Xing R; Guo L
Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):245-8. PubMed ID: 7587887
[TBL] [Abstract][Full Text] [Related]
15. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line.
Komatsu F; Ishiguro K
Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424
[TBL] [Abstract][Full Text] [Related]
17. Correlation between ultrastructural and histochemical parameters in lymphokine-activated killer (LAK) cells reacting with target cells in vitro.
Nano R; Barni S; Capelli E; Cremaschi P; Catanese C; Tomaselli S; Nascimbene C; Prosperi E
Acta Oncol; 1994; 33(2):165-9. PubMed ID: 7515629
[TBL] [Abstract][Full Text] [Related]
18. Effects of reactive oxygen species on lymphokine-activated killer cells in patients with bladder cancer.
Wang ZP; Chen YR; Zheng RL; Lu JZ; Wang JJ
Acta Pharmacol Sin; 2002 Mar; 23(3):257-62. PubMed ID: 11918852
[TBL] [Abstract][Full Text] [Related]
19. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
Falk CS; Noessner E; Weiss EH; Schendel DJ
Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
[TBL] [Abstract][Full Text] [Related]
20. Cytoskeleton actin changes in IL-2 activated cells.
Capelli E; Nano R; Panelli S; Sciola L; Spano A; Barni S
Eur J Histochem; 2000; 44(3):279-83. PubMed ID: 11095099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
